February 15th 2021, 10:30pm
Patients with ovarian cancer who lived within 10 miles of Kansas’s only National Cancer Institute–designated cancer center, and those of a non-White race, were shown to have less of a survival advantage.
February 12th 2021, 5:00pm
Whitney Goldsberry, MD, clinician at the University of Alabama at Birmingham Hospital and fellow at the UAB Division of Gynecologic Oncology, gives her insight into the future of PARP inhibitors in ovarian cancer treatment.
February 11th 2021, 12:00am
An investigation of 24 women from the United Kingdom’s PROTECTOR trial has revealed that their concerns toward cancer risk and menopause affect their choice of surgery as treatment for ovarian cancer.
February 6th 2021, 5:00am
Whitney Goldsberry, MD, fellow at the University of Alabama's Division of Gynecologic Oncology, discusses findings from her and colleagues' recent analysis of cost-sharing trends for PARP inhibitors in ovarian cancer treatment.
February 5th 2021, 1:00pm
Researchers from MD Anderson Cancer Center found that laparoscopy cost more upfront but eliminated wasteful treatment decisions.
January 30th 2021, 6:00pm
Recent results with adavosertib in ovarian cancer could signal future positive results, given the number of trials using the targeted therapy with the PARP inhibitor olaparib.
January 20th 2021, 5:00pm
Lauren M. Corduck, who turned a diagnosis of ovarian cancer into a crusade to educate others with similar genetic mutations, died on December 24, 2020. She was 49.
January 15th 2021, 10:30pm
Certain elderly women with ovarian cancer might benefit from aggressive treatment methods, a study recently published in Annals of Surgical Oncology found.
January 15th 2021, 5:00pm
Panel testing for genetic variants linked to more cancers is cost-effective than just testing or BRCA1/2 mutations, says a clinical director for a women's health company.
January 9th 2021, 9:15pm
Daniel F. Hayes, MD, offers definitions and an algorithm for clinicians to define clinical utility.
